|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
24 October 2016 |
|
Main ID: |
NCT01085266 |
|
Date of registration:
|
10/03/2010 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
HORIZON PLUS |
|
Scientific title:
|
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease |
|
Date of first enrolment:
|
February 2010 |
|
Target sample size:
|
362 |
|
Recruitment status: |
Terminated |
|
URL:
|
https://clinicaltrials.gov/show/NCT01085266 |
|
Study type:
|
Interventional |
|
Study design:
|
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
Phase:
|
Phase 3
|
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Successful completion of 26 weeks of blinded treatment in the HORIZON study
Exclusion Criteria:
- Any other medical illness or unstable medical condition that may interfere with their
ability to comply with study procedures and abide by study restrictions, or may
interfere with the ability to interpret safety information.
Age minimum:
30 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Huntington Disease
|
|
Intervention(s)
|
|
Drug: Dimebon (latrepirdine)
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|